Your browser doesn't support javascript.
loading
Characterization of natural human antagonistic soluble CD40 isoforms produced through alternative splicing.
Eshel, Dani; Toporik, Amir; Efrati, Tali; Nakav, Sigal; Chen, Aviva; Douvdevani, Amos.
Afiliación
  • Eshel D; Compugen Ltd., Tel Aviv 69512, Israel.
Mol Immunol ; 46(2): 250-7, 2008 Dec.
Article en En | MEDLINE | ID: mdl-18849075
ABSTRACT
CD40, a TNF receptor (TNFR) family member, is composed of four cysteine rich domains (CRDs) followed by a transmembrane domain and a signaling intracellular C-terminus. CD154 ligation to CD40 regulates major inflammatory and immune processes. A natural soluble form of CD40 was detected in uremic patient's serum which might be alternative splicing product. Our aim was to identify CD40 isoforms produced by primary human cells and to evaluate their biological activity. By RT-PCR, we isolated from primary human cells three major products differing from the expected wild type (WT) transcript which lacks exon 5 (CD40-5), exon 6 (CD40-6) and both exons 5 and 6 (CD40-5 + 6). The first two were predicted computationally to be soluble decoy receptors with various CRDs numbers. Recombinant soluble CD40 (sCD40) isoforms containing either three or four CRDs are able to bind coated surfaces or membranous CD154 while the sCD40 isoform containing 2 CRDs did not. sCD40 proteins inhibited RANTES secretion, but did not block B cell proliferation induced by soluble CD154. These data suggest that sCD40 natural isoforms encompassing either three or four CRDs might exert different antagonistic effects from known CD154 antibodies by recognition of only membranous CD154.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Empalme Alternativo / Antígenos CD40 / Ligando de CD40 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Mol Immunol Año: 2008 Tipo del documento: Article País de afiliación: Israel

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Empalme Alternativo / Antígenos CD40 / Ligando de CD40 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Mol Immunol Año: 2008 Tipo del documento: Article País de afiliación: Israel